As of Tuesday’s last check, Aditxt Inc. (ADTX) was up 20.43% at $2.83 in pre-market trading hours. ADTX closed the last trading session unchanged at $2.35. Shares of ADTX traded between $2.27 and $2.55. ADTX traded 0.71 million shares, which was higher than its daily average of 0.27 million shares over 100 days. ADTX stock gained 2.17% in the last five days, while they lost -10.31% last month. Recent developments may provide more insight into ADTX stock as it has risen without current news.

ADTX has anything new happened recently?

Aditxt develops technologies specifically focused on the improvement of immune health through immune monitoring and reprogramming. In the ADTX immune monitoring technology, a comprehensive immune profile is provided to each patient on a personal basis. ADTX’s immune reprogramming technology is currently at the preclinical stage and targets transplant rejection, autoimmune diseases, and allergies by retraining the immune system to induce tolerance.

Aditxt announced a new and improved version of its AditxtScore for COVID-19.

• AditxtScore for COVID-19 is a multidimensional immune response test that monitors several combinations of the immune system’s reactions to certain antigens at the same time.
• ADTX also enhanced its AditxtScore for COVID-19 to include a SARS-CoV-2 virus neutralizing antibody test, allowing it to assess an individual’s immune response.
• AditxtScore for COVID-19 was released in August of 2020.
• By comparing multiple antigens associated with the SARS-CoV-2 virus, it provides a detailed picture of an individual’s immune response.
• The multi-multiplex screening tool developed by ADTX gives an individual a comprehensive picture of their immune response based on an expanded set of biomarkers associated with SARS-CoV-2.
• AditxtScore for COVID-19 now includes the ability to measure neutralizing antibodies, which are virus-specific antibodies that prevent infection by preventing viral particles from entering cells.
• As a result of AditxtScore’s precision and ability to measure individual’s reaction to COVID-19, clinicians can better understand a patient’s immune response to COVID-19, whether incurred through exposure, infection or vaccination.
• This tool can also identify individuals who are susceptible to SARS-CoV-2 infection for a variety of reasons, such as their inability to respond adequately to vaccination or infection, as well as their lack of prior exposure to the virus.

How ADTX Stock will be leveraging AditxtScore?

Based on ADTX’s research on individual immune responses to COVID-19 and COVID-19 vaccinations, ADTX found that the intensity, duration, and timing of antibody responses can vary widely. AditxtScore with neutralizing antibody diagnostics for COVID-19 enables ADTX to provide more detailed information about how well a person’s immune system responds to the virus as more people become vaccinated or exposed to the virus.